Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab for moderate to very severe COPD
NL-OMON59642Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Annualized rate of moderate or severe COPD exacerbations. Started Aug 2025; status: recruiting.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON59642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59642.